These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 24460542)

  • 1. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms.
    Ganai SA; Shanmugam K; Mahadevan V
    J Biomol Struct Dyn; 2015; 33(2):374-87. PubMed ID: 24460542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes.
    Kalyaanamoorthy S; Chen YP
    Biochim Biophys Acta; 2013 Jan; 1834(1):317-28. PubMed ID: 23457710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantum polarized ligand docking investigation to understand the significance of protonation states in histone deacetylase inhibitors.
    Kalyaanamoorthy S; Chen YP
    J Mol Graph Model; 2013 Jul; 44():44-53. PubMed ID: 23732305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
    Kashyap K; Kakkar R
    J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells.
    Ganai SA; Kalladi SM; Mahadevan V
    J Biomol Struct Dyn; 2015; 33(6):1185-97. PubMed ID: 25012937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural exploration of common pharmacophore based berberine derivatives as novel histone deacetylase inhibitor targeting HDACs enzymes.
    Kandasamy S; Selvaraj M; Muthusamy K; Varadaraju N; Kannupal S; Sekar AK; Vilwanathan R
    J Biomol Struct Dyn; 2023 Mar; 41(5):1690-1703. PubMed ID: 34994284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
    Ganai SA
    Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
    Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
    J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative
    Kashyap K; Kakkar R
    J Biomol Struct Dyn; 2021 Feb; 39(2):502-517. PubMed ID: 31900046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
    Gupta R; Ambasta RK; Kumar P
    Life Sci; 2020 Sep; 256():117912. PubMed ID: 32504755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
    Wang DF; Helquist P; Wiech NL; Wiest O
    J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
    Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
    Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial
    Ganai SA; Abdullah E; Rashid R; Altaf M
    Front Mol Neurosci; 2017; 10():357. PubMed ID: 29170627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
    Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
    J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-function analysis of the conserved tyrosine and diverse π-stacking among class I histone deacetylases: a QM (DFT)/MM MD study.
    Zhou J; Xie H; Liu Z; Luo HB; Wu R
    J Chem Inf Model; 2014 Nov; 54(11):3162-71. PubMed ID: 25360823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the design and synthesis of selective HDAC inhibitors.
    Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
    Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potent HDAC 2 inhibitors using E-pharmacophore modelling, structure-based virtual screening and molecular dynamic simulation.
    Pai P; Kumar A; Shetty MG; Kini SG; Krishna MB; Satyamoorthy K; Babitha KS
    J Mol Model; 2022 Apr; 28(5):119. PubMed ID: 35419753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
    Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
    ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Silico Identification of Potential Inhibitor Against a Fungal Histone Deacetylase, RPD3 from
    Shanmugam G; Kim T; Jeon J
    Molecules; 2019 May; 24(11):. PubMed ID: 31151320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.